BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 16340245)

  • 1. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
    Nisman B; Heching N; Biran H; Barak V; Peretz T
    Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
    Huang Z; Xu D; Zhang F; Ying Y; Song L
    Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
    Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.
    Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V
    Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
    Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
    Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
    Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
    Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

  • 15. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
    Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
    Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y; Wang Y; Li J; Hao X; Hu X
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.
    Ono A; Naito T; Ito I; Watanabe R; Shukuya T; Kenmotsu H; Tsuya A; Nakamura Y; Murakami H; Kaira K; Takahashi T; Kameya T; Nakajima T; Endo M; Yamamoto N
    Lung Cancer; 2012 Jun; 76(3):439-44. PubMed ID: 22300752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.